Affiris scores funding
Affiris AG, an Austrian developer of therapeutic peptide vaccines against chronic diseases, has secured 10 million euros in funding. The investors included FCPB Affi GmbH. Also, the company has named Günther Staffler as chief technology officer.
27 June 2016•1 min read
